Literature DB >> 9708468

Elevated serum concentrations of cardiac troponin T in acute allograft rejection after human heart transplantation.

T J Dengler1, R Zimmermann, K Braun, M Müller-Bardorff, J Zehelein, F U Sack, P A Schnabel, W Kübler, H A Katus.   

Abstract

OBJECTIVES: This study evaluates the concept and diagnostic efficacy of using serum troponin T for the detection of cardiac graft rejection.
BACKGROUND: Cardiac troponin T is a cardiospecific myofibrillar protein, which is only detectable in the circulation after cardiac myocyte damage. It might be expected to be released during acute heart allograft rejection, allowing noninvasive rejection diagnosis.
METHODS: In 35 control subjects and in 422 samples from 95 clinically unremarkable heart allograft recipients more than 3 months postoperatively, troponin T serum concentrations were compared to the histological grade of acute graft rejection in concurrent endomyocardial biopsies.
RESULTS: Mean troponin T serum concentrations were identical in control subjects (23.2 +/- 1.4 ng/liter) and in heart transplant recipients without graft rejection (International Society for Heart and Lung Transplantation [ISHLT] grade 0; 22.4 +/- 1.7 ng/liter). Mean troponin T concentrations increased in parallel with the severity of graft rejection (ISHLT grade 1: 27.8 +/- 1.8 ng/liter; grade 2: 33.2 +/- 2.7 ng/liter; grade 3A: 54.6 +/- 6.5 ng/liter; grade 3B and 4: 105.4 +/- 53.7 ng/liter; p < 0.001 for grades 3 and 4 vs. grades 0 and 1). The proportion of positive samples also increased in parallel with rejection severity, reaching 100% in rejections of grade 3B and 4. Sensitivity and specificity for the detection of significant graft rejection (ISHLT grade 3/4) were 80.4% and 61.8%, respectively. The negative predictive value was most remarkable with 96.2%. Intraindividual longitudinal analysis of troponin T levels and biopsy results in 15 patients during long-term follow-up confirmed these findings.
CONCLUSIONS: The present data demonstrate that acute allograft rejection after human heart transplantation is often associated with increased serum concentrations of troponin T. All cases of serious forms of graft rejection would have been detected before the development of clinical symptoms. Measurement of troponin T levels may become a useful ancillary parameter for noninvasive rejection diagnosis, being most valuable in the exclusion of severe cardiac graft rejection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9708468     DOI: 10.1016/s0735-1097(98)00257-5

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  15 in total

1.  Proceedings of the 4th Invitational Wintergreen Conference. Wintergreen, Virginia, USA. July 12-14, 1998. Abstracts.

Authors: 
Journal:  J Nucl Cardiol       Date:  1999 Jan-Feb       Impact factor: 5.952

Review 2.  Novel Biomarker Approaches for Managing Patients With Cardiac Transplantation.

Authors:  Peter J Kennel; P Christian Schulze
Journal:  Curr Heart Fail Rep       Date:  2015-10

Review 3.  Differential diagnosis of elevated troponins.

Authors:  Susanne Korff; Hugo A Katus; Evangelos Giannitsis
Journal:  Heart       Date:  2006-07       Impact factor: 5.994

Review 4.  [Biomarker for diagnosis of rejection after heart transplantation].

Authors:  Matthias Frick; Herwig Antretter; Otmar Pachinger; Gerhard Pölzl
Journal:  Herz       Date:  2010-01       Impact factor: 1.443

5.  Diagnostic performance of cardiac magnetic resonance for the detection of acute cardiac allograft rejection: a systematic review and meta-analysis.

Authors:  Wei Lu; Jun Zheng; Xu-Dong Pan; Ming-Duo Zhang; Tie-Yuan Zhu; Bin Li; Li-Zhong Sun
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

6.  Doppler tissue imaging for assessing left ventricular diastolic dysfunction in heart transplant rejection.

Authors:  S M Stengel; Y Allemann; M Zimmerli; E Lipp; N Kucher; P Mohacsi; C Seiler
Journal:  Heart       Date:  2001-10       Impact factor: 5.994

7.  Troponin T concentrations 72 hours after myocardial infarction as a serological estimate of infarct size.

Authors:  M Licka; R Zimmermann; J Zehelein; T J Dengler; H A Katus; W Kübler
Journal:  Heart       Date:  2002-06       Impact factor: 5.994

Review 8.  Where, when and how much: regulation of myelin proteolipid protein gene expression.

Authors:  P A Wight; A Dobretsova
Journal:  Cell Mol Life Sci       Date:  2004-04       Impact factor: 9.261

9.  Multicenter Analysis of Immune Biomarkers and Heart Transplant Outcomes: Results of the Clinical Trials in Organ Transplantation-05 Study.

Authors:  R C Starling; J Stehlik; D A Baran; B Armstrong; J R Stone; D Ikle; Y Morrison; N D Bridges; P Putheti; T B Strom; M Bhasin; I Guleria; A Chandraker; M Sayegh; K P Daly; D M Briscoe; P S Heeger
Journal:  Am J Transplant       Date:  2015-08-10       Impact factor: 8.086

Review 10.  Non-invasive cardiac allograft rejection surveillance: reliability and clinical value for prevention of heart failure.

Authors:  Michael Dandel; Roland Hetzer
Journal:  Heart Fail Rev       Date:  2020-09-05       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.